Now showing items 1-9 of 9

    • A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer. 

      Del Campo, JM; Birrer, M; Davis, C; Fujiwara, K; Gollerkeri, A; Gore, M; Houk, B; Lau, S; Poveda, A; González-Martín, A; Muller, C; Muro, K; Pierce, K; Suzuki, M; Vermette, J; Oza, A (2016-07)
      Objective PF-04691502 and gedatolisib (PF-05212384) are potent, dual PI3K/mTOR inhibitors. This phase II study (B1271004) was conducted in patients with recurrent endometrial cancer following platinum-containing chemotherapy. ...
    • Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial. 

      Corrie, PG; Marshall, A; Nathan, PD; Lorigan, P; Gore, M; Tahir, S; Faust, G; Kelly, CG; Marples, M; Danson, SJ; Marshall, E; Houston, SJ; Board, RE; Waterston, AM; Nobes, JP; Harries, M; Kumar, S; Goodman, A; Dalgleish, A; Martin-Clavijo, A; Westwell, S; Casasola, R; Chao, D; Maraveyas, A; Patel, PM; Ottensmeier, CH; Farrugia, D; Humphreys, A; Eccles, B; Young, G; Barker, EO; Harman, C; Weiss, M; Myers, KA; Chhabra, A; Rodwell, SH; Dunn, JA; Middleton, MR; AVAST-M Investigators; Nathan, P; Lorigan, P; Dziewulski, P; Holikova, S; Panwar, U; Tahir, S; Faust, G; Thomas, A; Corrie, P; Sirohi, B; Kelly, C; Middleton, M; Marples, M; Danson, S; Lester, J; Marshall, E; Ajaz, M; Houston, S; Board, R; Eaton, D; Waterston, A; Nobes, J; Loo, S; Gray, G; Stubbings, H; Gore, M; Harries, M; Kumar, S; Goodman, A; Dalgleish, A; Martin-Clavijo, A; Marsden, J; Westwell, S; Casasola, R; Chao, D; Maraveyas, A; Marshall, E; Patel, P; Ottensmeier, C; Farrugia, D; Humphreys, A; Eccles, B; Dega, R; Herbert, C; Price, C; Brunt, M; Scott-Brown, M; Hamilton, J; Hayward, RL; Smyth, J; Woodings, P; Nayak, N; Burrows, L; Wolstenholme, V; Wagstaff, J; Nicolson, M; Wilson, A; Barlow, C; Scrase, C; Podd, T; Gonzalez, M; Stewart, J; Highley, M; Wolstenholme, V; Grumett, S; Goodman, A; Talbot, T; Nathan, K; Coltart, R; Gee, B; Gore, M; Farrugia, D; Martin-Clavijo, A; Marsden, J; Price, C; Farrugia, D; Nathan, K; Coltart, R; Nathan, K; Coltart, R (2018-08)
      Background Bevacizumab is a recombinant humanised monoclonal antibody to vascular endothelial growth factor shown to improve survival in advanced solid cancers. We evaluated the role of adjuvant bevacizumab in melanoma ...
    • Long-Term Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma: A Pooled Analysis of Clinical Trials. 

      Tannir, NM; Figlin, RA; Gore, ME; Michaelson, MD; Motzer, RJ; Porta, C; Rini, BI; Hoang, C; Lin, X; Escudier, B (2017-06-20)
      Background We characterized clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib who were long-term responders (LTRs), defined as patients having progression-free survival (PFS) ...
    • Rare non-epithelial ovarian neoplasms: Pathology, genetics and treatment. 

      Foulkes, WD; Gore, M; McCluggage, WG (2016-07)
      Rare non-epithelial ovarian neoplasms have posed management challenges for many years. Their rarity means that most specialist practitioners will see one such case every several years, and most generalists may never see a ...
    • Sorafenib dose escalation in treatment-naïve patients with metastatic renal cell carcinoma: a non-randomised, open-label, Phase 2b study. 

      Gore, ME; Jones, RJ; Ravaud, A; Kuczyk, M; Demkow, T; Bearz, A; Shapiro, J; Strauss, UP; Porta, C (2017-06)
      Objective To assess the efficacy and safety of sorafenib dose escalation in metastatic renal cell carcinoma (mRCC).Patients and methods Intra-patient dose escalation may enhance the clinical benefit of targeted anticancer ...
    • Sunitinib in the treatment of metastatic renal cell carcinoma. 

      Schmid, TA; Gore, ME (2016-12)
      Sunitinib is an oral multi-targeted tyrosine kinase inhibitor (TKI) that targets various receptors, including vascular endothelial growth factor receptors (VEGFRs). Sunitinib received approval in 2006 and became a standard ...
    • The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin. 

      Wang, Y; Bernhardy, AJ; Cruz, C; Krais, JJ; Nacson, J; Nicolas, E; Peri, S; van der Gulden, H; van der Heijden, I; O'Brien, SW; Zhang, Y; Harrell, MI; Johnson, SF; Candido Dos Reis, FJ; Pharoah, PDP; Karlan, B; Gourley, C; Lambrechts, D; Chenevix-Trench, G; Olsson, H; Benitez, JJ; Greene, MH; Gore, M; Nussbaum, R; Sadetzki, S; Gayther, SA; Kjaer, SK; kConFab Investigators; D'Andrea, AD; Shapiro, GI; Wiest, DL; Connolly, DC; Daly, MB; Swisher, EM; Bouwman, P; Jonkers, J; Balmaña, J; Serra, V; Johnson, N (2016-05)
      Breast and ovarian cancer patients harboring BRCA1/2 germline mutations have clinically benefitted from therapy with PARP inhibitor (PARPi) or platinum compounds, but acquired resistance limits clinical impact. In this ...
    • The histology of ovarian cancer: worldwide distribution and implications for international survival comparisons (CONCORD-2). 

      Matz, M; Coleman, MP; Sant, M; Chirlaque, MD; Visser, O; Gore, M; Allemani, C; & the CONCORD Working Group (2017-02)
      Objective Ovarian cancers comprise several histologically distinct tumour groups with widely different prognosis. We aimed to describe the worldwide distribution of ovarian cancer histology and to understand what role this ...